Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Hills Bank & Trust Co

Hills Bank & Trust Co lowered its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,960 shares of the medical equipment provider’s stock after selling 123 shares during the period. Hills Bank & Trust Co’s holdings in Zimmer Biomet were worth $2,709,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Raymond James Trust N.A. grew its holdings in shares of Zimmer Biomet by 13.8% during the second quarter. Raymond James Trust N.A. now owns 6,327 shares of the medical equipment provider’s stock worth $687,000 after buying an additional 766 shares during the last quarter. Kanawha Capital Management LLC increased its holdings in shares of Zimmer Biomet by 25.0% in the second quarter. Kanawha Capital Management LLC now owns 2,178 shares of the medical equipment provider’s stock valued at $236,000 after purchasing an additional 435 shares during the period. Family Firm Inc. purchased a new stake in shares of Zimmer Biomet during the second quarter worth approximately $33,000. Horizon Bancorp Inc. IN lifted its holdings in shares of Zimmer Biomet by 18.6% during the second quarter. Horizon Bancorp Inc. IN now owns 1,477 shares of the medical equipment provider’s stock worth $160,000 after purchasing an additional 232 shares during the period. Finally, HMS Capital Management LLC grew its position in Zimmer Biomet by 6.8% in the 2nd quarter. HMS Capital Management LLC now owns 5,847 shares of the medical equipment provider’s stock valued at $635,000 after buying an additional 370 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ZBH shares. Citigroup reduced their target price on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Argus raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a report on Tuesday, May 21st. Piper Sandler downgraded Zimmer Biomet from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $140.00 to $115.00 in a research note on Monday, July 1st. Barclays dropped their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a report on Friday, May 31st. Finally, Raymond James decreased their target price on shares of Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $127.11.

Zimmer Biomet Price Performance

NYSE:ZBH traded up $1.63 during trading hours on Friday, reaching $115.05. 788,447 shares of the company traded hands, compared to its average volume of 1,388,773. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $133.90. The stock has a market cap of $23.67 billion, a P/E ratio of 24.90, a P/E/G ratio of 2.02 and a beta of 1.01. The firm’s 50-day moving average is $108.98 and its 200-day moving average is $117.60. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.02. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.82 earnings per share. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.06 earnings per share for the current fiscal year.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.